{{Rsnum
|rsid=1945771
|Gene=SLC6A5
|Chromosome=11
|position=20632075
|Orientation=plus
|GMAF=0.3003
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=SLC6A5
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 10.8 | 46.2 | 43.1
| HCB | 6.7 | 48.9 | 44.4
| JPT | 9.1 | 50.0 | 40.9
| YRI | 1.6 | 25.4 | 73.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 6.7 | 48.9 | 44.4
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=20859245
|Title=Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol
}}